Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company biOasis Technologies Inc.
DescriptionTrastuzumab conjugated to the Transcend p97 carrier protein
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationBrain cancer
Indication DetailsTreat brain metastasis in patients with HER2+ breast cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today